Import from '@womanrx/ui'

Repatha vs Lisinopril: What to Do When One Fails

Why Comparing These Two Drugs Is the Wrong Starting Question

The question "Repatha vs lisinopril" comes up because women and their clinicians want to know which drug to use when their cardiometabolic risk is not under control. The answer starts with identifying which risk factor is out of range.

Repatha and lisinopril do not compete with each other. One drug lowers LDL cholesterol through PCSK9 blockade. The other lowers blood pressure and blunts the renin-angiotensin-aldosterone system. Choosing between them is like choosing between a statin and a beta-blocker: the choice depends on the problem, not on a head-to-head preference.

If your LDL is 160 mg/dL and your blood pressure is well controlled, lisinopril will not help your LDL. If your blood pressure is 155/95 mmHg and your LDL is at goal, Repatha will not lower your blood pressure. The only scenario where a genuine choice exists is a woman who needs cardiovascular risk reduction and has not yet started either drug, and even then the guideline-based answer is to treat both problems, not to pick one.

The Actual Clinical Question Behind This Search

When women search "what to do when one fails," they usually mean one of three things.

First, the drug was tried and did not move the target number enough. Second, the drug caused side effects that forced a stop. Third, insurance denied coverage and the woman needs an alternative path.

Each scenario has a different answer. The rest of this article walks through each one, with specific attention to how your life stage, hormonal status, and reproductive plans change the decision.

How Repatha (Evolocumab) Works and When It Fails

Repatha is a monoclonal antibody that binds PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, Repatha allows more LDL receptors to cycle back to the cell surface, pulling more LDL out of circulation.

In the FOURIER trial, evolocumab added to statin therapy reduced LDL-C by 59% from a median baseline of 92 mg/dL, reaching a median on-treatment LDL of 30 mg/dL, and cut the composite major adverse cardiovascular event (MACE) endpoint by 15% over a median 2.2 years.

When Repatha Is Considered to Have Failed

Repatha "fails" in four distinct ways.

Insufficient LDL lowering. This is uncommon with correct dosing and injection technique, but it happens. Possible reasons include antibody formation (rare with evolocumab), incorrect storage (the drug must be refrigerated and allowed to reach room temperature before injection), or a very high baseline LDL that cannot reach guideline targets even with a 60% reduction.

Injection site reactions or serious allergy. Approximately 2.1% of participants in FOURIER experienced injection-site reactions. Severe hypersensitivity is rare but does occur.

Insurance denial or cost failure. This is the most common "failure" in practice. PCSK9 inhibitors remain among the most expensive drugs in the lipid-lowering class, and prior authorization criteria are strict at many commercial payers. This is a systems problem, not a pharmacological one.

Patient-initiated discontinuation. Injection aversion, needle phobia, or the biweekly or monthly schedule being unmanageable leads some women to stop without telling their clinician.

What to Do When Repatha Fails

When Repatha fails for LDL reasons, the next step is not lisinopril. It is to reassess the lipid-lowering regimen. Options include maximizing statin dose, adding ezetimibe (which can lower LDL a further 15-20%), switching to alirocumab (the other approved PCSK9 inhibitor, Praluent), considering inclisiran (an siRNA approach dosed twice yearly), or, for heterozygous or homozygous familial hypercholesterolemia, adding lomitapide or evinacumab.

For women specifically, a thyroid panel is worth checking before escalating lipid therapy. Hypothyroidism is more common in women and raises LDL substantially. Treating undiagnosed hypothyroidism can drop LDL by 15-30 mg/dL without adding another lipid drug.

How Lisinopril Works and When It Fails

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. It blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. The result is lower blood pressure, reduced afterload on the heart, and, in the kidneys, reduced intraglomerular pressure, which slows the progression of diabetic nephropathy.

The ALLHAT trial, which enrolled 33,357 participants with hypertension and at least one other cardiovascular risk factor, found that lisinopril was slightly less effective than chlorthalidone at reducing blood pressure (systolic BP was 2 mmHg higher in the lisinopril arm at five years), and was associated with higher rates of stroke in Black participants. ALLHAT remains the largest antihypertensive outcomes trial ever conducted.

When Lisinopril Is Considered to Have Failed

Inadequate blood pressure control. Lisinopril at maximum dose (40 mg daily) may not bring blood pressure to goal in women with obesity, high-salt diets, chronic kidney disease, or secondary hypertension (renal artery stenosis, primary aldosteronism).

ACE inhibitor cough. This is the most common reason women stop lisinopril. The dry, persistent cough caused by bradykinin accumulation occurs in approximately 10-15% of patients overall but is roughly twice as common in women and is even higher in East Asian women, affecting up to 30-40% in some studies. If cough forces a stop, the correct switch is to an angiotensin receptor blocker (ARB) such as losartan or valsartan, not to Repatha.

Hyperkalemia. Women with diabetes, chronic kidney disease stage 3 or above, or who take NSAIDs regularly are at elevated risk. Potassium above 5.5 mEq/L typically requires dose reduction or discontinuation.

Angioedema. Rare but potentially life-threatening. Black women face a three-to-four-fold higher risk of ACE inhibitor-associated angioedema compared to white women. If angioedema occurs, ACE inhibitors are permanently contraindicated. The switch is to an ARB with awareness that cross-reactivity, while uncommon, exists.

What to Do When Lisinopril Fails

If lisinopril fails for blood pressure reasons, the path forward depends on the failure mechanism. Cough: switch to an ARB. Angioedema: switch to an ARB with caution, or consider a calcium channel blocker or thiazide as the backbone. Insufficient effect: add a calcium channel blocker (amlodipine is first choice in most guidelines), or consider a thiazide diuretic, particularly chlorthalidone based on ALLHAT data. Secondary hypertension should be ruled out before adding a third agent.

Again, Repatha does not lower blood pressure. Adding it to a failed antihypertensive regimen will not help your blood pressure.

Women-Specific Physiology: How Hormones Change Everything

This framework for thinking about cardiometabolic failure by life stage is not widely published in a single place. It synthesizes data from multiple sources to give you a practical map.

Reproductive Years (Ages 18-40)

Estrogen is broadly cardioprotective during reproductive years. LDL tends to be lower, HDL higher, and the blood pressure distribution is shifted left compared to age-matched men. This does not mean cardiovascular disease is absent. Women with PCOS have insulin resistance, dyslipidemia (elevated triglycerides, low HDL, small dense LDL), and a higher rate of hypertension than age-matched women without PCOS, often requiring early cardiometabolic intervention.

For women with PCOS, the lipid pattern that responds best to PCSK9 inhibition is the high LDL variant. The more common PCOS lipid pattern (high triglycerides, low HDL) responds better to weight loss, metformin, and fibrates. A PCSK9 inhibitor is not indicated for isolated hypertriglyceridemia.

Perimenopause (Ages 40-55, Approximately)

Estrogen withdrawal during perimenopause drives LDL up by 10-20 mg/dL on average, often crossing guideline treatment thresholds for the first time. Arterial stiffness increases. Blood pressure rises. Many women who were well-controlled on a statin alone suddenly need add-on therapy, and many normotensive women develop stage 1 or stage 2 hypertension within two to three years of menopause transition.

This is the life stage where a woman is most likely to need both Repatha (or an escalated lipid regimen) and an antihypertensive like lisinopril simultaneously. The framing of "which one" breaks down entirely at this point. Both may be necessary.

Menopausal hormone therapy (MHT) has complex effects on lipids. Oral estradiol raises HDL and lowers LDL but raises triglycerides. Transdermal estradiol has a more neutral lipid profile. The Menopause Society recommends individualized cardiovascular risk assessment before and during MHT. MHT does not replace statins or PCSK9 inhibitors for women with established ASCVD.

Post-Menopause

LDL rises further. Blood pressure control becomes harder as arterial compliance decreases. The evidence base for Repatha in post-menopausal women is extrapolated from FOURIER, where women were 29% of enrollees. The sex-specific cardiovascular outcomes data showed a consistent directional benefit in women, but the trial was not powered to detect a statistically significant effect in the female subgroup alone. This is an honest evidence gap. The benefit is plausible and guideline-supported, but not proven in women with the same statistical rigor as in men.

For hypertension in post-menopausal women, lisinopril remains a reasonable first-line choice, though ALLHAT data suggest chlorthalidone may be superior for major cardiovascular event reduction in older, higher-risk populations.

Pregnancy and Lactation: Both Drugs Are Contraindicated

This section is not optional reading.

Lisinopril in Pregnancy

Lisinopril carries an FDA teratogenicity warning equivalent to former Category D in the second and third trimesters and Category X at those stages by many reference standards. ACE inhibitors cause fetal renal tubular dysplasia, oligohydramnios, neonatal renal failure, skull ossification defects, limb contractures, and death. The risk is highest in the second and third trimesters, but first-trimester exposure is also associated with cardiovascular and CNS malformations in some observational data.

Lisinopril must be stopped before conception. Women of reproductive age taking lisinopril for hypertension or diabetic nephropathy should be counseled at every visit about the need to switch to a pregnancy-compatible antihypertensive (labetalol, nifedipine, or methyldopa are preferred) the moment they are planning pregnancy or have a positive test.

Lisinopril is detectable in breast milk in small amounts. Given availability of safer alternatives, most guidelines recommend against use during lactation.

Repatha (Evolocumab) in Pregnancy

Evolocumab has no adequate human pregnancy data. The FDA label recommends avoiding use during pregnancy because animal data showed adverse developmental effects at high doses and because LDL-cholesterol is biologically necessary for fetal development, particularly for steroid hormone synthesis and cell membrane formation. Lowering maternal LDL to very low levels during fetal organogenesis carries theoretical concern.

Women of reproductive age taking Repatha should use effective contraception. Repatha is not a known teratogen in the way lisinopril is, but human safety data are absent, and the precautionary principle applies.

Evolocumab is a large biologic antibody. IgG antibodies do transfer into breast milk, but GI degradation of large proteins means systemic absorption by the infant is likely minimal. Formal lactation safety data do not exist. The decision to continue Repatha while breastfeeding should involve a frank conversation between the woman and her cardiologist about the maternal cardiovascular risk of stopping versus the theoretical infant risk of exposure.

Contraception Counseling for Women on These Drugs

Any woman of reproductive age taking lisinopril should be on reliable contraception if pregnancy is not planned and should have a clear "what to do if I get pregnant" plan documented in her chart. This is not a formality. ACE inhibitor teratogenicity is severe and the first trimester window before women know they are pregnant is exactly when organogenesis occurs.

Who This Is Right For and Who It Is Not

Repatha is appropriate for you if:

• You have established ASCVD (prior heart attack, stroke, symptomatic peripheral artery disease) and LDL remains above 70 mg/dL on maximally tolerated statin therapy.
• You have heterozygous or homozygous familial hypercholesterolemia.
• You are statin-intolerant and LDL is substantially above goal.
• You are in perimenopause or post-menopause and your LDL has crossed the treatment threshold for the first time despite lifestyle changes.

Repatha is not appropriate for you if:

• Your primary uncontrolled problem is blood pressure.
• Your LDL is already at goal and you want additional cardiovascular protection (the benefit is LDL-mediated).
• You are pregnant or planning pregnancy within the next six months and have not discussed a bridging plan with your clinician.
• You have isolated hypertriglyceridemia without elevated LDL.

Lisinopril is appropriate for you if:

• You have hypertension that has not responded adequately to lifestyle changes.
• You have heart failure with reduced ejection fraction.
• You are post-MI and need cardioprotective ACE inhibition.
• You have diabetic kidney disease (lisinopril slows progression of albuminuria).
• You are in perimenopause and your blood pressure has risen above 130/80 mmHg persistently.

Lisinopril is not appropriate for you if:

• You are pregnant or trying to conceive.
• You have a history of ACE inhibitor-associated angioedema.
• Your primary uncontrolled problem is elevated LDL.
• Your potassium is persistently above 5.0 mEq/L at baseline.

Can You Take Both Repatha and Lisinopril Together?

Yes. There is no pharmacokinetic or pharmacodynamic interaction between evolocumab and lisinopril. They work through entirely different pathways and on different organ systems.

A woman with established ASCVD, an LDL of 95 mg/dL on high-intensity statin, and a blood pressure of 148/92 mmHg may appropriately be on both drugs at the same time. The combination is standard-of-care in high-risk women with both dyslipidemia and hypertension.

The combination does not require any special monitoring beyond what each drug demands individually: LDL panel every three to six months on Repatha, basic metabolic panel (creatinine, potassium) and blood pressure monitoring on lisinopril.

A Practical Decision Map When One Drug Fails

Start by confirming which target is out of range. Then match the failure to its most likely cause.

LDL not at goal on Repatha: Check injection technique and storage. Confirm the statin backbone is maximized. Rule out hypothyroidism. Consider adding ezetimibe. Consider switching to alirocumab or inclisiran if cost or schedule is the barrier.

Blood pressure not at goal on lisinopril: Rule out secondary causes. Add amlodipine as the first add-on agent. Consider switching to chlorthalidone-based therapy if lisinopril is not tolerable. If cough is the issue, switch to losartan or valsartan, not to Repatha.

Both targets out of range: Both drugs (or their successors) may be needed simultaneously. A cardiology or women's health specialist referral is appropriate when both LDL and blood pressure remain uncontrolled despite at least two agents for each target.

Insurance denial for Repatha: Work with your clinician on a prior authorization appeal using FOURIER outcome data and LDL documentation. Amgen's patient assistance program (Repatha Purluma) may cover cost for qualifying women. This is a step worth taking before abandoning the drug.

"Women presenting in the menopausal transition with newly elevated LDL and newly elevated blood pressure represent a dual-target challenge that single-drug thinking will always fail to address," notes Dr. Elena Vasquez, MD, WomanRx editorial board reviewer and board-certified in obstetrics, gynecology, and women's cardiovascular health. "The clinical question is not which drug to choose. It is whether we have correctly identified every active risk factor and whether each one has an adequate treatment plan."